Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ay 27773
2. Ay-27,773
3. N-((5-(trifluoromethyl)-6-methoxy-1-naphthalenyl)thioxomethyl)-n-methylglycine
4. N-5-trifluoromethyl-6-methoxy-1-thionaphthoyl-n-methylglycine
1. 82964-04-3
2. Alredase
3. Lorestat
4. Tolrestatin
5. Ay-27773
6. Tolrestatum
7. Ay-27,773
8. Ay 27773
9. 2-(6-methoxy-n-methyl-5-(trifluoromethyl)naphthalene-1-carbothioamido)acetic Acid
10. Chembl436
11. 0t93lg5nmk
12. N-(6-methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine
13. Chebi:48549
14. N-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-n-methylglycine
15. 2-[[6-methoxy-5-(trifluoromethyl)naphthalene-1-carbothioyl]-methylamino]acetic Acid
16. Ncgc00183862-01
17. N-(6-methoxy-5-(trifluoromethyl)naphthalene-1-carbonothioyl)-n-methylglycine
18. Glycine, N-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methyl-
19. Tolrestatum [latin]
20. N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-n-methylglycine
21. 2-{1-[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]-n-methylmethanethioamido}acetic Acid
22. N-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methylglycine
23. N-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-n-methylglycine
24. Tol
25. Unii-0t93lg5nmk
26. N-[6-methoxythio-5-(trifluoromethyl)-1-naphthoyl]sarcosine
27. Alrestin
28. Tolrestat [usan:inn:ban]
29. Glycine, N-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-n-methyl-
30. Alredase (tn)
31. Tolrestat [inn]
32. Tolrestat [mi]
33. Tolrestat (usan/inn)
34. Tolrestat [usan]
35. Tolrestat [mart.]
36. Tolrestat [who-dd]
37. Dsstox_cid_28760
38. Dsstox_rid_83029
39. Dsstox_gsid_48834
40. Schembl49326
41. Gtpl7404
42. Bdbm16314
43. Dtxsid80904890
44. Bcpp000039
45. Bcp02377
46. Zinc3780343
47. Tox21_113316
48. Akos005146007
49. Cs-2040
50. Db02383
51. Vs-0127
52. N-((6-methoxy-5-(trifluoromethyl)naphthalen-1-yl)thioxomethyl)-n-methylglycine
53. Hy-16500
54. Cas-75820-08-5
55. Ft-0753651
56. A13083
57. C01621
58. D02323
59. 964t043
60. J-522752
61. Q7814620
62. [([6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbothioyl)(methyl)amino]acetic Acid #
63. [(6-methoxy-5-trifluoromethyl-naphthalene-1-carbothioyl)-methyl-amino]-acetic Acid
64. 2-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]-n-methylmethanethioamido}acetic Acid
65. N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-n-methylglycine
| Molecular Weight | 357.3 g/mol |
|---|---|
| Molecular Formula | C16H14F3NO3S |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 357.06464897 g/mol |
| Monoisotopic Mass | 357.06464897 g/mol |
| Topological Polar Surface Area | 81.9 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 486 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the pharmacological control of certain diabetic complications.
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10X - Other drugs used in diabetes
A10XA - Aldose reductase inhibitors
A10XA01 - Tolrestat
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Tolrestat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tolrestat, including repackagers and relabelers. The FDA regulates Tolrestat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tolrestat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tolrestat supplier is an individual or a company that provides Tolrestat active pharmaceutical ingredient (API) or Tolrestat finished formulations upon request. The Tolrestat suppliers may include Tolrestat API manufacturers, exporters, distributors and traders.
click here to find a list of Tolrestat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tolrestat DMF (Drug Master File) is a document detailing the whole manufacturing process of Tolrestat active pharmaceutical ingredient (API) in detail. Different forms of Tolrestat DMFs exist exist since differing nations have different regulations, such as Tolrestat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tolrestat DMF submitted to regulatory agencies in the US is known as a USDMF. Tolrestat USDMF includes data on Tolrestat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tolrestat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tolrestat suppliers with USDMF on PharmaCompass.
Tolrestat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tolrestat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tolrestat GMP manufacturer or Tolrestat GMP API supplier for your needs.
A Tolrestat CoA (Certificate of Analysis) is a formal document that attests to Tolrestat's compliance with Tolrestat specifications and serves as a tool for batch-level quality control.
Tolrestat CoA mostly includes findings from lab analyses of a specific batch. For each Tolrestat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tolrestat may be tested according to a variety of international standards, such as European Pharmacopoeia (Tolrestat EP), Tolrestat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tolrestat USP).
LOOKING FOR A SUPPLIER?
